Wall Street is positive on Corvus Pharmaceuticals Inc (CRVS). On average, analysts give the stock a Strong Buy rating. The average price target is $8.6, which means analysts expect the stock to increase by 143.63% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 65, which is better than 65% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Corvus Pharmaceuticals Inc Stock Today?
Corvus Pharmaceuticals Inc (CRVS) stock is down -10.41% while the S&P 500 is up 0.11% as of 11:20 AM on Friday, Feb 12. CRVS is lower by -$0.41 from the previous closing price of $3.94 on volume of 2,131,578 shares. Over the past year the S&P 500 has risen 16.20% while CRVS is lower by -19.77%. CRVS lost -$1.51 per share the over the last 12 months.